High-intensity Interval Training Versus Moderate Intensity Continuous Training as a Means to Improve Cardiometabolic Health After Spinal Cord Injury
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Metabolic Syndrome
- Sponsor
- Brock University
- Enrollment
- 8
- Locations
- 1
- Primary Endpoint
- Waist circumference (inches)
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
Testing the efficacy of high intensity interval training (HIIT), as compared to current research supporting moderate intensity continuous training (MICT), as a means to improve cardiometabolic health after spinal cord injury.
Detailed Description
This study aims to challenge the effectiveness of the current aerobic exercise recommendations for individuals with spinal cord injuries (SCI). Currently, moderate intensity continuous training (MICT) is suggested however this study intends to explore the effectiveness of high intensity interval training (HIIT). To do so, approximately 8 individuals with SCI will be undergo a 6 week HIIT intervention consisting of 3 sessions per week. With a focus on cardiometabolic health markers (listed in outcome measure section), we aim to provide support for HIIT as a viable method of mitigating cardiovascular risk in a SCI population.
Investigators
David Ditor
David Ditor, PhD - Professor, Kinesiology
Brock University
Eligibility Criteria
Inclusion Criteria
- •Individuals with a spinal cord injury (paraplegia or tetraplegia, complete or incomplete) who are at least one-year post injury.
- •Declared medically stable, and able to communicate clearly in English.
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Waist circumference (inches)
Time Frame: 6 weeks
Central adiposity will be measured by tape measure to monitor possible weight loss
Cholesterol
Time Frame: 6 weeks
Total and HDL cholesterol will be measured in serum
Triglycerides
Time Frame: 6 weeks
Triglycerides will be measured in serum
Glycated Hemoglobin (HbA1c)
Time Frame: 6 weeks
Glycated hemoglobin will be measured in whole blood as an indicator of diabetic risk
Tumor necrosis factor (TNF-a)
Time Frame: 6 weeks
TNF-a will be used as an inflammatory representative and will be measured in serum
Interleukin - 10 (IL-10)
Time Frame: 6 weeks
IL-10 will will be used as an anti-inflammatory representative and will be measured in serum
Pulse Wave Velocity
Time Frame: 6 weeks
Arterial stiffness, a common measure for cardiac risk will be measured
Adiponectin
Time Frame: 6 weeks
Adiponectin will will be used as a surrogate for insulin resistance and will be measured in serum
Blood pressure
Time Frame: 6 weeks
Measured through a digital cuff, the focus will be on both systolic and diastolic
Peak Oxygen Consumption (VO2 peak)
Time Frame: 6 weeks
VO2 peak will be measured by a Moxus metabolic cart to determine changes in fitness
C Reactive Protein (CRP)
Time Frame: 6 weeks
CRP will will be used as an inflammatory representative and will be measured in serum
Leptin
Time Frame: 6 weeks
Leptin will will be used as a body fat representative and will be measured in serum
Secondary Outcomes
- Physical Activity Enjoyment Scale (PACES)(6 weeks)